John Wolleben's questions to Madrigal Pharmaceuticals Inc (MDGL) leadership • Q3 2024
Question
An analyst on behalf of John Wolleben asked how payers are currently managing patients on both GLP-1 therapies and Rezdiffra, and how this might predict future dynamics if a GLP-1 is approved for NASH.
Answer
CEO William Sibold estimated that approximately 25% of Rezdiffra patients are concurrently using a GLP-1 for comorbidities, with market research suggesting up to 50% have prior exposure. He explained that physicians are treating NASH as a distinct condition requiring Rezdiffra, regardless of a patient's GLP-1 history, which he believes positions the company strongly for any future market changes.